Decisions about the distribution of limited financial resources in the NHS and other health care systems can be aided by a cost-utility analysis. This study aimed to undertake a cost-utility analysis to establish the cost per quality adjusted life years (cost/QALY) of ETF in patients with cerebrovascular accident (CVA), one of the largest patient groups registered with the British Artificial Nutrition Survey (BANS).
The cost (£) /QALY for patients receiving ETF in their own home (£12 817) was below the threshold of £30 000 (1) and considerably lower than if the patients remained in an NHS hospital (£171 727/QALY, assuming the same outcome). In nursing home patients, the cost/ QALY varied considerably depending on the contributions made by the state to non-medical costs (Table) .
This data suggests that currently ETF is much more cost-effective for the health care system, when used in the home or in nursing homes (where the non-medical costs are paid privately) than in NHS hospitals. The cost-effectiveness of ETF is less in a nursing home when the state pays all non-medical costs, raising issues of economic and ethical concern.
